FDA Proposes Ban on Compounded Obesity and Diabetes Drugs, Names New Acting Director
The FDA proposed excluding semaglutide and tirzepatide from compounding lists, citing no clinical need. Katherine Szarama was named acting director of...
The FDA proposed excluding semaglutide and tirzepatide from compounding lists, citing no clinical need. Katherine Szarama was named acting director of...
The FDA has proposed excluding semaglutide and tirzepatide, key ingredients in popular weight-loss and diabetes drugs like Wegovy, Ozempic, Mounjaro,...
A new study suggests tirzepatide medications like Mounjaro may lead to greater lean body mass loss compared to semaglutide drugs like Ozempic. Researc...
A new retrospective study presented at the American Academy of Neurology annual meeting suggests GLP-1 drugs like Ozempic may increase cognitive impai...
A large Swedish study published in The Lancet Psychiatry suggests GLP-1 receptor agonists like Ozempic and Wegovy may lower the risk of worsening depr...
The FDA has approved a 7.2 mg weekly dose of Wegovy, a GLP-1 medication, for weight loss. Clinical trials show this higher dose can lead to 25% more w...
The FDA banned 19 peptide drugs for compounding pharmacies in 2023 due to safety concerns. Now, under HHS Secretary RFK Jr., the agency may reverse th...